Literature DB >> 12654261

Gene silencing by systemic delivery of synthetic siRNAs in adult mice.

Dag R Sørensen1, Marianne Leirdal, Mouldy Sioud.   

Abstract

In mammalian cells, RNA duplexes of 21-23 nucleotides, known as small interfering RNAs (siRNAs) specifically inhibit gene expression in vitro. Here, we show that systemic delivery of siRNAs can inhibited exogenous and endogenous gene expression in adult mice. Cationic liposome-based intravenous injection in mice of plasmid encoding the green fluorescent protein (GFP) with its cognate siRNA, inhibited GFP gene expression in various organs. Furthermore, intraperitoneal injection of anti-TNF-alpha siRNA inhibited lipopolysaccharide-induced TNF-alpha gene expression, whereas secretion of IL1-alpha was not inhibited. Importantly, the development of sepsis in mice following a lethal dose of lipopolysaccharide injection, was significantly inhibited by pre-treatment of the animals with anti-TNF-alpha siRNAs. Collectively, these results demonstrate that synthetic siRNAs can function in vivo as pharmaceutical drugs. Copyright 2003 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654261     DOI: 10.1016/s0022-2836(03)00181-5

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  116 in total

Review 1.  Strategies for identifying genes that play a role in spinal cord regeneration.

Authors:  M Wintzer; M Mladinic; D Lazarevic; C Casseler; A Cattaneo; J Nicholls
Journal:  J Anat       Date:  2004-01       Impact factor: 2.610

2.  A novel approach for evaluating the efficiency of siRNAs on protein levels in cultured cells.

Authors:  Weilin Wu; Emily Hodges; Jenny Redelius; Christer Höög
Journal:  Nucleic Acids Res       Date:  2004-01-22       Impact factor: 16.971

3.  CRE recombinase-inducible RNA interference mediated by lentiviral vectors.

Authors:  Gustavo Tiscornia; Vinay Tergaonkar; Francesco Galimi; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-30       Impact factor: 11.205

Review 4.  Pharmaceutical prospects for RNA interference.

Authors:  Raymond M Schiffelers; Martin C Woodle; Puthupparampil Scaria
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

Review 5.  Induction of RNA interference in dendritic cells.

Authors:  Mu Li; Hua Qian; Thomas E Ichim; Wei-Wen Ge; Igor A Popov; Katarzyna Rycerz; John Neu; David White; Robert Zhong; Wei-Ping Min
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice.

Authors:  Sandra M Ocampo; Carolina Romero; Anna Aviñó; Joan Burgueño; Miguel A Gassull; Jordi Bermúdez; Ramon Eritja; Ester Fernandez; Jose C Perales
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

7.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

Review 8.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

9.  Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis.

Authors:  Bumseok Kim; Qingquan Tang; Partha S Biswas; Jun Xu; Raymond M Schiffelers; Frank Y Xie; Aslam M Ansari; Puthupparampil V Scaria; Martin C Woodle; Patrick Lu; Barry T Rouse
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

10.  Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference.

Authors:  Sung-Suk Chae; Ji-Hye Paik; Henry Furneaux; Timothy Hla
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.